The O
antigen B
- I
specific I
IgG4 I
antibody I
seems O
to O
be O
an O
index O
in O
evaluating O
immunotherapy O
objectively O
. O

This O
strategy O
was O
used O
to O
place O
both O
the O
Tn903 B
neo I
gene I
and O
the O
Rhodosporidium B
toruloides I
phenylalanine I
ammonia I
lyase I
( O
PAL B
) O
- O
encoding O
gene O
under O
the O
transcriptional O
control O
of O
pPGK B
: O
: O
REP2 B
. O

Phosphatidylinositol B
3 I
- I
kinase I
requirement O
in O
activation O
of O
the O
ras B
/ O
C B
- I
raf I
- I
1 I
/ O
MEK B
/ O
ERK B
and O
p70 B
( O
s6k B
) O
signaling O
cascade O
by O
the O
insulinomimetic O
agent O
vanadyl O
sulfate O
. O

The O
5 O
' O
flanking O
region O
contains O
potential O
binding O
sites O
for O
TATA B
- I
binding I
protein I
, O
Sp1 B
, O
nuclear B
factor I
1 I
( O
NF1 B
) O
, O
CAAT B
- I
box I
binding I
protein I
( O
C B
/ I
EBP I
) O
, O
hepatocyte B
nuclear I
factors I
1 I
and I
5 I
( O
HNF1 B
, O
HNF5 B
) O
and O
activator B
proteins I
1 I
and I
2 I
( O
AP1 B
, O
AP2 B
) O
. O

The O
5 O
' O
flanking O
region O
contains O
potential O
binding O
sites O
for O
TATA B
- I
binding I
protein I
, O
Sp1 B
, O
nuclear B
factor I
1 I
( O
NF1 B
) O
, O
CAAT B
- I
box I
binding I
protein I
( O
C B
/ I
EBP I
) O
, O
hepatocyte B
nuclear I
factors I
1 I
and I
5 I
( O
HNF1 B
, O
HNF5 B
) O
and O
activator B
proteins I
1 I
and I
2 I
( O
AP1 B
, O
AP2 B
) O
. O

Targeted O
disruption O
of O
the O
OGG1 B
gene I
in O
yeast O
revealed O
a O
second O
OG B
glycosylase I
/ I
lyase I
protein I
, O
tentatively O
named O
Ogg2 B
, O
which O
differs O
from O
Ogg1 B
in O
that O
it O
preferentially O
acts O
on O
OG O
: O
G O
. O

These O
data O
are O
consistent O
with O
the O
idea O
that O
the O
neuron B
- I
specific I
SCG10 I
gene I
evolved O
by O
duplication O
and O
modification O
of O
the O
more O
broadly O
expressed O
stathmin B
/ O
Lap18 B
gene O
. O

These O
results O
suggest O
that O
UBP41 B
may O
play O
an O
important O
role O
in O
the O
recycling O
of O
ubiquitin B
by O
hydrolysis O
of O
branched B
poly I
- I
ubiquitin I
chains I
generated O
by O
the O
action O
of O
26 B
S I
proteasome I
on O
poly O
- O
ubiquitinated O
protein O
substrates O
, O
as O
well O
as O
in O
the O
production O
of O
free O
ubiquitin B
from O
linear B
poly I
- I
ubiquitin I
chains I
and O
of O
certain O
ribosomal O
proteins O
from O
ubiquitin B
fusion I
proteins I
. O

These O
results O
suggest O
that O
UBP41 B
may O
play O
an O
important O
role O
in O
the O
recycling O
of O
ubiquitin B
by O
hydrolysis O
of O
branched B
poly I
- I
ubiquitin I
chains I
generated O
by O
the O
action O
of O
26 B
S I
proteasome I
on O
poly O
- O
ubiquitinated O
protein O
substrates O
, O
as O
well O
as O
in O
the O
production O
of O
free O
ubiquitin B
from O
linear B
poly I
- I
ubiquitin I
chains I
and O
of O
certain O
ribosomal O
proteins O
from O
ubiquitin B
fusion I
proteins I
. O

In O
patients O
with O
type O
IA O
maple O
syrup O
urine O
disease O
, O
the O
E1alpha B
subunit I
is O
affected O
, O
resulting O
in O
the O
loss O
of O
E1 B
and O
branched B
- I
chain I
ketoacid I
dehydrogenase I
catalytic O
activities O
. O

Several O
7SL B
RNA I
- I
encoding I
sequences I
and O
various O
intergenic O
spacers O
were O
amplified O
from O
the O
individual O
HindIII B
fragments I
of O
about O
1 O
. O
3 O
and O
2 O
. O
8 O
kb O
. O

Dilutions O
of O
H B
- I
2b I
or I
H I
- I
2d I
NP I
peptides I
indicated O
that O
3 O
- O
4 O
logs O
less O
H B
- I
2b I
NP I
peptide I
was O
required O
to O
sensitize O
syngeneic O
target O
cells O
for O
CTL O
- O
specific O
lysis O
, O
suggesting O
that O
the O
differing O
affinities O
of O
H O
- O
2b O
and O
H O
- O
2d O
major B
histocompatibility I
complex I
molecules I
for O
their O
peptides O
likely O
account O
for O
the O
total O
removal O
of O
NP O
CTL O
in O
the O
H O
- O
2b O
mice O
but O
only O
partial O
removal O
in O
H O
- O
2d O
mice O
made O
to O
express O
thymic O
NP O
. O

The O
recombinant O
contains O
the O
normal O
beta B
A I
- I
globin I
gene I
, O
the O
mutant O
gene O
and O
Ylp O
vector O
sequences O
between O
the O
two O
copies O
. O

Alternative O
splicing O
of O
ClC B
- I
6 I
( O
a O
member O
of O
the O
CIC B
chloride I
- I
channel I
family I
) O
transcripts O
generates O
three O
truncated O
isoforms O
one O
of O
which O
, O
ClC B
- I
6c I
, O
is O
kidney O
- O
specific O
. O

Comparison O
with O
the O
sequence O
databanks O
show O
that O
Tactile B
is O
a O
member O
of O
the O
immunoglobulin B
gene I
superfamily I
, O
with O
similarity O
to O
Drosophila B
amalgam I
, O
the O
melanoma B
Ag I
MUC I
- I
18 I
, O
members O
of O
the O
carcinoembryonic B
Ag I
family I
, O
the O
poliovirus B
receptor I
, O
and O
the O
neural B
cell I
adhesion I
molecule I
. O

Paracrine O
activation O
of O
the O
HIV B
- I
1 I
LTR I
promoter I
by O
the O
viral B
Tat I
protein I
is O
mechanistically O
similar O
to O
trans O
- O
activation O
within O
a O
cell O
. O

Pseudosubstrate O
( O
19 O
- O
36 O
) O
, O
derived O
from O
the O
C O
- O
terminus O
of O
Ca B
- I
dependent I
PKC I
isotypes I
, O
inhibited O
beta B
- I
PKC I
but O
not O
nPKC B
activity O
using O
either O
Histone B
IIIS I
or O
peptide O
( O
19 O
- O
31 O
) O
as O
substrate O
. O

Nucleotide O
sequences O
between O
the O
env B
gene I
and O
the O
LTR B
of I
SFV I
- I
1 I
were O
determined O
. O

The O
novel O
hematopoietic B
growth I
factor I
FLT3 I
ligand I
( O
FL B
) O
is O
the O
cognate O
ligand O
for O
the O
FLT3 B
, O
tyrosine B
kinase I
receptor I
( O
R B
) O
, O
also O
referred O
to O
as O
FLK B
- I
2 I
and O
STK B
- I
1 I
. O

Oncogenic O
activation O
of O
the O
tyrosine B
kinase I
domain I
of O
the O
human B
trk I
proto I
- I
oncogene I
by O
fusion O
to O
a O
cell O
adhesion O
molecule O
. O

Members O
of O
the O
Ras B
subfamily I
of O
small B
GTP I
- I
binding I
proteins I
have O
been O
shown O
to O
be O
promiscuous O
towards O
a O
variety O
of O
putative O
effector O
molecules O
such O
as O
the O
protein B
kinase I
c I
- I
Raf I
and O
the O
Ral B
- I
specific I
guanine I
nucleotide I
exchange I
factor I
( O
Ral B
- I
GEF I
) O
. O

Members O
of O
the O
Ras B
subfamily I
of O
small B
GTP I
- I
binding I
proteins I
have O
been O
shown O
to O
be O
promiscuous O
towards O
a O
variety O
of O
putative O
effector O
molecules O
such O
as O
the O
protein B
kinase I
c I
- I
Raf I
and O
the O
Ral B
- I
specific I
guanine I
nucleotide I
exchange I
factor I
( O
Ral B
- I
GEF I
) O
. O

Regions O
rich O
in O
serine O
, O
threonine O
, O
and O
proline O
residues O
can O
be O
found O
in O
transcriptional O
activation O
domains O
, O
as O
well O
as O
in O
the O
N O
- O
terminal O
parts O
of O
mammalian B
TATA I
- I
binding I
proteins I
, O
where O
they O
are O
interrupted O
by O
polyglutamine O
stretches O
. O

We O
have O
previously O
demonstrated O
that O
expression O
of O
the O
gene O
for O
the O
reproductive O
neuropeptide O
, O
GnRH B
, O
is O
repressed O
by O
the O
glutamate O
/ O
NO O
/ O
cyclic O
GMP O
( O
cGMP O
) O
signal O
transduction O
pathway O
through O
cGMP B
- I
dependent I
protein I
kinase I
in O
the O
hypothalamic O
GnRH B
- O
secreting O
neuronal O
cell O
line O
GT1 O
- O
7 O
. O

A O
comparison O
of O
the O
promoters O
for O
muMIP B
- I
1 I
beta I
and O
muMIP B
- I
1 I
alpha I
reveals O
a O
conserved O
CK O
- O
1 O
element O
, O
but O
transient O
expression O
studies O
in O
RAW O
264 O
. O
7 O
macrophages O
with O
proximal O
fragments O
of O
either O
the O
muMIP B
- I
1 I
beta I
or O
the O
muMIP B
- I
1 I
alpha I
5 I
' I
promoter I
fused O
to O
a O
human B
growth I
hormone I
reporter I
gene I
link O
LPS O
- O
inducibility O
in O
both O
to O
promoter O
segments O
near O
to O
, O
but O
not O
identical O
with O
, O
the O
consensus O
CK O
- O
1 O
sequence O
. O

( O
2 O
) O
Erythroid O
32D O
Epo1 B
cells O
showed O
a O
lower O
level O
of O
bulk O
PKC B
catalytic O
activity O
, O
lacked O
the O
expression O
of O
epsilon B
and I
eta I
PKC I
isoforms I
, O
and O
showed O
a O
weak O
or O
absent O
upregulation O
of O
the O
remaining O
isoforms O
, O
except O
betaI B
, O
upon O
readdition O
of O
Epo B
to O
growth O
factor O
- O
starved O
cells O
. O

Previous O
work O
has O
shown O
that O
spleen B
necrosis I
virus I
( I
SNV I
) I
long I
terminal I
repeats I
( O
LTRs O
) O
are O
associated O
with O
Rex B
/ O
Rex B
- O
responsive O
element O
- O
independent O
expression O
of O
bovine O
leukemia O
virus O
RNA O
and O
supports O
the O
hypothesis O
that O
SNV O
RNA O
contains O
a O
cis O
- O
acting O
element O
that O
interacts O
with O
cellular B
Rex I
- I
like I
proteins I
. O

Because O
the O
Pit B
- I
1 I
sites I
in O
the O
hGH B
- I
N I
gene I
promoter I
are O
insufficient O
for O
such O
gene O
activation O
in O
vivo O
, O
these O
data O
suggested O
a O
unique O
chromatin O
- O
mediated O
developmental O
role O
for O
Pit B
- I
1 I
in O
the O
hGH B
LCR I
. O

In O
293 O
cells O
, O
expression O
of O
the O
NF B
- I
kappa I
B I
inhibitor O
, O
I B
kappa I
B I
- I
alpha I
, O
reduced O
the O
stimulatory O
activity O
of O
LMP B
. O

Expression O
of O
a O
dominant B
- I
negative I
ras I
gene I
also O
blocks O
TIS10 B
/ O
PGS2 B
induction O
by O
v B
- I
src I
. O

Moreover O
, O
the O
hypoxia O
- O
induced O
expression O
of O
the O
endogenous O
Epo B
gene I
was O
significantly O
inhibited O
in O
Hep3B O
cells O
stably O
transfected O
with O
HNF B
- I
4 I
delta I
C I
. O

Alternative O
splicing O
of O
fibroblast B
growth I
factor I
receptor I
2 I
( O
FGF B
- I
R2 I
) O
is O
an O
example O
of O
highly O
regulated O
alternative O
splicing O
in O
which O
exons O
IIIb O
and O
IIIc O
are O
utilized O
in O
a O
mutually O
exclusive O
manner O
in O
different O
cell O
types O
. O

Surprisingly O
, O
there O
is O
no O
sequence O
homology O
between O
this O
region O
of O
Ly B
- I
6E I
and O
the O
established O
consensus O
for O
the O
interferon B
- I
stimulated I
response I
element I
, O
which O
has O
been O
shown O
functionally O
important O
to O
all O
previously O
characterized O
alpha B
/ I
beta I
interferon I
- O
inducible O
promoters O
. O

The O
relation O
between O
myocardial B
beta I
- I
adrenergic I
receptor I
and O
left O
ventricular O
( O
LV O
) O
function O
was O
studied O
in O
10 O
patients O
, O
aged O
41 O
to O
61 O
years O
( O
average O
51 O
) O
, O
with O
LV O
volume O
overload O
mainly O
due O
to O
chronic O
mitral O
regurgitation O
. O

This O
0 O
. O
74 O
kb O
cDNA O
contains O
an O
open O
reading O
frame O
( O
ORF O
) O
of O
477 O
bp O
encoding O
a O
polypeptide O
of O
159 O
amino O
acids O
( O
aa O
) O
which O
differs O
at O
only O
one O
position O
( O
position O
65 O
) O
from O
the O
human B
U1 I
- I
C I
protein I
. O

Me O
( O
2 O
) O
SO O
- O
induced O
neuronal O
differentiation O
of O
N1E O
- O
115 O
neuroblastoma O
cells O
increased O
both O
the O
expression O
of O
the O
endogenous B
Ntr I
- I
1 I
gene I
and O
reporter O
genes O
driven O
by O
NTR B
- I
1 I
promoter I
sequences I
by O
3 O
- O
4 O
- O
fold O
. O

Me O
( O
2 O
) O
SO O
- O
induced O
neuronal O
differentiation O
of O
N1E O
- O
115 O
neuroblastoma O
cells O
increased O
both O
the O
expression O
of O
the O
endogenous B
Ntr I
- I
1 I
gene I
and O
reporter O
genes O
driven O
by O
NTR B
- I
1 I
promoter I
sequences I
by O
3 O
- O
4 O
- O
fold O
. O

The O
novel O
Notch B
homologue I
mouse B
Notch I
3 I
lacks O
specific O
epidermal B
growth I
factor I
- I
repeats I
and O
is O
expressed O
in O
proliferating O
neuroepithelium O
. O

Gene O
and O
pseudogene O
of O
the O
mouse O
cation O
- O
dependent O
mannose B
6 I
- I
phosphate I
receptor I
. O

Seven O
clones O
encoding O
interferon B
response I
element I
binding I
factors I
have O
been O
isolated O
from O
a O
mouse O
fibroblast O
lambda O
gt11 O
cDNA O
library O
by O
using O
a O
32P O
end O
- O
labeled O
tandem O
trimer O
of O
the O
mouse B
( I
2 I
' I
- I
5 I
' I
) I
oligoadenylate I
synthetase I
gene I
interferon O
response O
element O
as O
a O
probe O
. O

Evidence O
for O
a O
role O
of O
endogenous B
corticotropin I
- I
releasing I
factor I
in O
cold O
, O
ether O
, O
immobilization O
, O
and O
traumatic O
stress O
. O

Nodular O
involvement O
of O
the O
left O
lung O
and O
infiltration O
of O
the O
mucosa O
of O
the O
left O
lower O
lobe O
bronchus O
followed O
very O
gradually O
and O
a O
monoclonal O
gammopathy O
( O
IgA B
- I
- I
Type I
Kappa I
) O
was O
demonstrated O
. O

These O
results O
suggest O
that O
G B
beta I
gamma I
- O
stimulated O
Shc B
phosphorylation O
represents O
an O
early O
step O
in O
the O
pathway O
leading O
to O
p21ras B
activation O
, O
similar O
to O
the O
mechanism O
utilized O
by O
growth B
factor I
tyrosine I
kinase I
receptors I
. O

To O
understand O
the O
function O
of O
receptor B
- I
linked I
tyrosine I
phosphatases I
in O
neural O
development O
, O
we O
sought O
to O
identify O
LAR B
isoforms I
preferentially O
expressed O
in O
the O
nervous O
system O
and O
cellular O
processes O
regulating O
LAR B
alternative O
splicing O
. O

Sp1 B
can O
activate O
transcription O
through O
immunoglobulin B
kappa I
- I
chain I
enhancer I
or O
P B
- I
selectin I
promoter I
NF B
- I
kappaB I
sites I
. O

The O
bovine B
PGHS I
- I
2 I
cDNA I
was O
cloned O
by O
a O
combination O
of O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
and O
cDNA O
library O
screening O
. O

Exposure O
of O
peripheral O
blood O
T O
cells O
from O
young O
subjects O
to O
PHA B
or O
cross O
- O
linked O
anti B
- I
CD3 I
monoclonal I
antibodies I
stimulated O
rapid O
increases O
in O
MAPK B
and O
MEK B
enzymatic O
activity O
. O

The O
mutant O
allele O
of O
the O
alpha B
1 I
- I
tubulin I
gene I
was O
designated O
tua1 B
- I
1 I
. O

Competitive O
mobility O
shift O
assays O
using O
either O
alphaT3 O
- O
1 O
nuclear O
extract O
or O
recombinant B
SF I
- I
1 I
protein I
clearly O
indicated O
that O
SF B
- I
1 I
is O
able O
to O
interact O
specifically O
with O
this O
GSE B
element I
positioned O
at O
- O
134 O
. O

In O
both O
settings O
, O
it O
can O
be O
phosphorylated O
by O
cyclin B
D I
- I
dependent I
kinases I
, O
suggesting O
that O
its O
transcriptional O
activity O
may O
normally O
be O
regulated O
through O
such O
mechanisms O
. O

A O
polypeptide O
encoded O
by O
the O
NTS O
16 O
open O
reading O
frame O
has O
sequence O
similarity O
to O
the O
catalytic O
domain O
of O
several O
receptor B
protein I
kinases I
from I
plants I
including O
the O
S B
- I
receptor I
kinases I
implicated O
in O
the O
rejection O
of O
self O
- O
pollen O
in O
Brassica O
species O
and O
the O
Pto B
gene I
product I
of I
tomato I
which O
confers O
resistance O
to O
a O
bacterial O
pathogen O
. O

A O
polypeptide O
encoded O
by O
the O
NTS O
16 O
open O
reading O
frame O
has O
sequence O
similarity O
to O
the O
catalytic O
domain O
of O
several O
receptor B
protein I
kinases I
from I
plants I
including O
the O
S B
- I
receptor I
kinases I
implicated O
in O
the O
rejection O
of O
self O
- O
pollen O
in O
Brassica O
species O
and O
the O
Pto B
gene I
product I
of I
tomato I
which O
confers O
resistance O
to O
a O
bacterial O
pathogen O
. O

The O
ectopic O
expression O
of O
Oct B
- I
3 I
/ I
4 I
in O
hybrid O
cells O
under O
a O
constitutive O
promoter O
is O
sufficient O
for O
transcriptional O
activation O
of O
an O
octamer O
- O
dependent O
promoter O
. O

A O
role O
for O
glycogen B
synthase I
kinase I
- I
3 I
in O
the O
control O
of O
gene O
expression O
. O

Combined O
expression O
of O
c B
- I
Jun I
and O
p65 B
induced O
vigorous O
transcription O
of O
IL B
- I
2 I
promoter O
- O
and O
CD28RE B
- I
driven I
reporter I
constructs I
in O
both O
LFA B
- I
3 I
- O
and O
B7 B
- I
1 I
- O
costimulated O
Jurkat O
cells O
. O

Wild B
- I
type I
AT1A I
receptors I
, O
expressed O
in O
Chinese O
hamster O
ovary O
cells O
, O
rapidly O
internalized O
after O
Ang B
II I
stimulation O
[ O
t1 O
/ O
2 O
2 O
. O
3 O
min O
; O
maximal O
level O
of O
internalization O
( O
Ymax O
) O
78 O
. O
2 O
% O
] O
, O
as O
did O
mutant O
receptors O
carrying O
single O
acidic O
substitutions O
( O
T332E O
, O
t1 O
/ O
2 O
2 O
. O
7 O
min O
, O
Ymax O
76 O
. O
3 O
% O
; O
S335D O
, O
t1 O
/ O
2 O
2 O
. O
4 O
min O
, O
Ymax O
76 O
. O
7 O
% O
; O
T336E O
, O
t1 O
/ O
2 O
2 O
. O
5 O
min O
, O
Ymax O
78 O
. O
2 O
% O
; O

Insulin B
- I
like I
growth I
factor I
- I
binding I
protein I
- I
2 I
( O
IGF B
- I
BP I
- I
2 I
) O
transcription O
in O
rat O
liver O
varies O
with O
developmental O
age O
and O
fasting O
. O

Aryl B
hydrocarbon I
receptor I
nuclear I
translocator I
( O
ARNT B
) O
is O
a O
component O
of O
the O
transcription O
factors O
, O
aryl B
hydrocarbon I
receptor I
( O
AhR B
) O
and O
hypoxia B
- I
inducible I
factor I
1 I
, O
which O
transactivate O
their O
target O
genes O
, O
such O
as O
CYP1A1 B
and O
erythropoietin B
, O
in O
response O
to O
xenobiotic O
aromatic O
hydrocarbons O
and O
to O
low O
O2 O
concentration O
, O
respectively O
. O

Aryl B
hydrocarbon I
receptor I
nuclear I
translocator I
( O
ARNT B
) O
is O
a O
component O
of O
the O
transcription O
factors O
, O
aryl B
hydrocarbon I
receptor I
( O
AhR B
) O
and O
hypoxia B
- I
inducible I
factor I
1 I
, O
which O
transactivate O
their O
target O
genes O
, O
such O
as O
CYP1A1 B
and O
erythropoietin B
, O
in O
response O
to O
xenobiotic O
aromatic O
hydrocarbons O
and O
to O
low O
O2 O
concentration O
, O
respectively O
. O

Systematic O
functional O
analysis O
of O
V1a B
/ I
V2 I
hybrid I
receptors I
showed O
that O
the O
second O
intracellular O
loop O
of O
the O
V1a B
receptor I
is O
required O
and O
sufficient O
for O
efficient O
coupling O
to O
Gq B
/ I
11 I
, O
whereas O
the O
third O
intracellular O
loop O
of O
the O
V2 B
receptor I
is O
required O
and O
sufficient O
for O
coupling O
to O
Gs B
. O

Structure O
and O
expression O
of O
the O
mouse B
growth I
hormone I
receptor I
/ O
growth B
hormone I
binding I
protein I
gene I
. O

The O
second O
patient O
had O
received O
pituitary B
- I
derived I
growth I
hormone I
for O
treatment O
of O
growth B
hormone I
deficiency O
, O
secondary O
to O
a O
third O
ventricle O
teratoma O
, O
exised O
13 O
yr O
earlier O
. O

The O
normal O
cell O
cycle O
is O
regulated O
by O
several O
molecules O
, O
such O
as O
the O
tumor B
- I
suppressor I
protein I
pRb I
, O
the O
G1 B
cyclins I
, O
the O
cyclin B
- I
dependent I
kinases I
, O
and O
their O
inhibitors O
. O

This O
construct O
, O
termed O
pDeltaCREC B
/ O
EBP B
, O
binds O
C B
/ I
EBPalpha I
and I
beta I
but O
not O
CREB B
, O
yet O
it O
confers O
a O
nearly O
complete O
glucocorticoid O
response O
when O
transiently O
transfected O
into O
H4IIE O
rat O
hepatoma O
cells O
. O

Such O
an O
increase O
in O
the O
steady O
- O
state O
testicular B
TIMP I
- I
2 I
mRNA I
level O
apparently O
is O
not O
the O
result O
of O
an O
up O
- O
regulation O
by O
germ O
cells O
because O
germ O
cells O
cocultured O
with O
Sertoli O
cells O
failed O
to O
elicit O
an O
increase O
in O
the O
Sertoli O
cell O
steady O
- O
state O
TIMP B
- I
2 I
mRNA I
level O
. O

The O
expression O
of O
the O
yam8 B
( I
+ I
) I
cDNA I
in O
the O
mid1 B
mutant I
cells O
partially O
remediated O
the O
mid O
phenotype O
and O
resulted O
in O
a O
slight O
increase O
in O
Ca O
( O
2 O
+ O
) O
uptake O
activity O
. O

The O
promoter O
of O
the O
rat B
PGS I
- I
2 I
gene I
contains O
a O
CAAT B
enhancer I
- I
binding I
protein I
consensus I
site I
( I
CAAT I
box I
) I
which O
can O
confer O
hormone O
inducibility O
to O
a O
PGS B
- I
2 I
. O
CAT B
reporter O
gene O
, O
as O
well O
as O
a O
putative O
E O
- O
box O
region O
. O

The O
Ets B
- I
1 I
binding I
site I
was O
localized O
to O
a O
17 O
- O
base O
pair O
( O
bp O
) O
region O
from O
the O
3 O
' O
end O
of O
T B
alpha I
2 I
. O

The O
Cili B
- I
2 I
sequences I
possess O
similarity O
to O
the O
RNaseH B
domain I
of O
Lian B
- O
Aa1 B
, O
a O
mosquito B
non I
- I
LTR I
retrotransposon I
. O

Samples O
from O
1415 O
neurological O
patients O
were O
used O
to O
study O
the O
diagnostic O
value O
of O
acid B
alpha I
1 I
- I
glycoprotein I
in O
the O
lumbar O
cerebrospinal O
fluid O
. O

A O
sheep O
testicular O
cDNA O
library O
constructed O
in O
pcDNA1 O
vector O
was O
screened O
with O
a O
probe O
generated O
by O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
corresponding O
to O
a O
1 O
. O
6 O
kb O
fragment O
of O
the O
rat B
luteinizing I
hormone I
receptor I
cDNA I
. O

A O
mouse B
brain I
beta I
- I
spectrin I
of O
cDNA O
was O
identified O
within O
a O
lambda O
Gt11 O
expression O
library O
using O
an O
antibody O
which O
specifically O
binds O
with O
the O
235 B
kDa I
spectrin I
beta I
- I
subunit I
. O

We O
propose O
that O
CTS1 B
and I
CTS2 I
of I
Ci I
are O
members O
of O
two O
distinct O
classes O
of O
fungal B
chitinases I
, O
an O
observation O
not O
previously O
reported O
for O
a O
single O
fungus O
. O

The O
biosynthesis O
and O
stability O
of O
the O
three O
mutant O
proteins O
were O
similar O
to O
those O
of O
the O
wild B
- I
type I
erbB I
protein I
, O
and O
all O
three O
retained O
the O
ability O
to O
transform O
chicken O
embryo O
fibroblasts O
. O

The O
interferon B
- O
induced O
RNA B
- I
dependent I
protein I
kinase I
( O
PKR B
) O
is O
considered O
to O
play O
an O
important O
role O
in O
the O
cellular O
defense O
against O
viral O
infection O
and O
, O
in O
addition O
, O
has O
been O
suggested O
to O
be O
a O
tumor O
suppressor O
gene O
because O
of O
its O
growth O
- O
suppressive O
properties O
. O

We O
now O
demonstrate O
that O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
( I
C I
/ I
EBP I
) I
delta I
is O
a O
major O
component O
of O
a O
PGE2 O
- O
stimulated O
DNA O
- O
protein O
complex O
involving O
HS3D B
and O
find O
that O
C B
/ I
EBPdelta I
transactivates O
IGF B
- I
I I
promoter I
1 I
through O
this O
site O
. O

Transcriptional O
activity O
was O
measured O
by O
slot O
- O
blot O
hybridization O
with O
steady O
- O
state O
RNA O
isolated O
from O
lacZ B
+ I
M I
. I
smegmatis I
clones O
. O

This O
study O
indicates O
that O
the O
phenotype O
of O
myofibrillar O
disarray O
seen O
in O
HCM O
patients O
which O
harbor O
either O
of O
these O
two O
mutations O
may O
not O
be O
directly O
due O
to O
the O
failure O
of O
the O
mutant B
myosin I
heavy I
chain I
protein I
to O
assemble O
and O
form O
normal O
sarcomeres O
, O
but O
may O
rather O
be O
a O
secondary O
effect O
possibly O
resulting O
from O
the O
chronic O
stress O
of O
decreased O
beta B
MHC I
function O
. O

The O
DNase B
I I
footprint O
extended O
5 O
' O
in O
the O
silencer O
region O
to O
include O
an O
inverted O
repeat O
of O
a O
six O
- O
nucleotide O
motif O
( O
epsilon O
- O
267 O
to O
- O
278 O
bp O
) O
which O
shares O
5 O
of O
6 O
bases O
with O
the O
GATA B
- I
1 I
consensus I
sequence I
. O

Platelet B
- I
derived I
growth I
factor I
- O
dependent O
activation O
of O
phosphatidylinositol B
3 I
- I
kinase I
is O
regulated O
by O
receptor O
binding O
of O
SH2 B
- I
domain I
- I
containing I
proteins I
which O
influence O
Ras B
activity O
. O

A O
2 O
kb O
transcript O
was O
isolated O
from O
brain O
that O
encodes O
a O
approximately O
57 O
kDa O
protein O
; O
the O
predicted O
protein O
contains O
the O
known O
N B
- I
terminal I
Ets I
domain I
of O
PE1 B
and O
a O
novel O
C O
- O
terminal O
domain O
with O
signficant O
homology O
to O
murine B
ERF I
. O

The O
mechanism O
involves O
Gbetagamma B
subunit O
- O
mediated O
increases O
in O
tyrosine O
phosphorylation O
of O
the O
Shc B
adapter I
protein I
, O
Shc B
* O
Grb2 B
complex O
formation O
, O
and O
recruitment O
of O
Ras B
guanine I
nucleotide I
exchange I
factor I
activity O
. O

Another O
stem O
- O
loop O
called O
structure O
III O
near O
the O
3 O
' O
- O
end O
of O
repY B
sequesters O
both O
the O
5 O
' O
- O
rCGCC O
- O
3 O
' O
sequence O
and O
the O
repZ B
ribosome I
- I
binding I
site I
. O

In O
HCMV O
( O
Towne O
) O
- O
infected O
HF O
cells O
at O
24 O
to O
48 O
h O
, O
IE2 B
also O
accumulated O
in O
newly O
formed O
viral O
DNA O
replication O
compartments O
containing O
the O
polymerase B
processivity I
factor I
( O
UL44 B
) O
, O
the O
single B
- I
stranded I
DNA I
binding I
protein I
( O
SSB B
; O
UL57 B
) O
, O
the O
UL112 B
- I
113 I
accessory I
protein I
, O
and O
newly O
incorporated O
bromodeoxyuridine O
( O
BrdU O
) O
. O

Protein B
kinase I
A I
- I
Ialpha I
subunit O
- O
directed O
antisense O
inhibition O
of O
ovarian O
cancer O
cell O
growth O
: O
crosstalk O
with O
tyrosine B
kinase I
signaling O
pathway O
. O

Small B
Maf I
proteins I
heterodimerize O
with O
Fos B
and O
may O
act O
as O
competitive O
repressors O
of O
the O
NF B
- I
E2 I
transcription I
factor I
. O

A O
larval B
albumin I
- I
like I
protein I
was O
not O
detectable O
by O
silver O
staining O
in O
serum O
of O
tadpoles O
before O
the O
beginning O
of O
metamorphosis O
at O
stage O
48 O
. O

Consistent O
with O
the O
hypothesis O
that O
it O
acts O
as O
transcriptional O
regulator O
, O
wild B
- I
type I
p53 I
protein I
binds O
DNA O
and O
activates O
transcription O
of O
several O
promoters O
. O

These O
data O
support O
a O
possible O
biological O
significance O
of O
the O
frameshift O
to O
occur O
at O
this O
position O
of O
the O
large O
overlap O
by O
including O
the O
putative O
RNA O
template O
- O
binding O
site O
of O
the O
PLRV B
replicase I
in O
the O
ORF2a B
/ I
ORF2b I
transframe I
protein I
. O

Two O
polyadenylation O
sites O
were O
used O
, O
one O
at O
the O
end O
of O
the O
early B
( I
E I
) I
region I
of O
the O
viral O
DNA O
, O
the O
other O
at O
the O
end O
of O
the O
late B
( I
L I
) I
region I
. O

Two O
polyadenylation O
sites O
were O
used O
, O
one O
at O
the O
end O
of O
the O
early B
( I
E I
) I
region I
of O
the O
viral O
DNA O
, O
the O
other O
at O
the O
end O
of O
the O
late B
( I
L I
) I
region I
. O

The O
human O
cDNA O
was O
used O
to O
demonstrate O
that O
tumor B
necrosis I
factor I
- I
alpha I
could O
rapidly O
stimulate O
MARCKS B
gene I
transcription O
in O
the O
human O
promyelocytic O
leukemia O
cell O
line O
HL60 O
. O

In O
addition O
, O
a O
potent O
splicing O
enhancer O
sequence O
isolated O
in O
the O
selection O
specifically O
binds O
a O
20 B
- I
kDa I
SR I
protein I
. O

The O
observed O
phenotypes O
may O
be O
explained O
by O
( O
i O
) O
a O
selective O
disruption O
of O
very B
- I
low I
- I
density I
lipoprotein I
secretion O
due O
to O
decreased O
expression O
of O
genes O
encoding O
apolipoprotein B
B I
and O
microsomal B
triglyceride I
transfer I
protein I
, O
( O
ii O
) O
an O
increase O
in O
hepatic O
cholesterol O
uptake O
due O
to O
increased O
expression O
of O
the O
major O
high B
- I
density I
lipoprotein I
receptor I
, O
scavenger B
receptor I
BI I
, O
and O
( O
iii O
) O
a O
decrease O
in O
bile O
acid O
uptake O
to O
the O
liver O
due O
to O
down O
- O
regulation O
of O
the O
major O
basolateral B
bile I
acid I
transporters I
sodium I

Tyrosine O
phosphorylation O
of O
cellular O
proteins O
is O
the O
earliest O
identifiable O
event O
following O
T B
- I
cell I
antigen I
receptor I
( O
TCR B
) O
stimulation O
and O
is O
essential O
for O
activating O
downstream O
signaling O
machinery O
. O

To O
determine O
whether O
vanadate O
could O
inhibit O
PEPCK B
gene I
transcription O
, O
a O
series O
of O
chimeric O
genes O
containing O
several O
deletions O
in O
the O
P B
- I
enolypyruvate I
carboxykinase I
promoter I
between O
- O
550 O
and O
- O
68 O
was O
linked O
to O
the O
structural O
genes O
for O
either O
amino B
- I
3 I
- I
glycosyl I
phosphotransferase I
( O
neo B
) O
or O
chloramphenicol B
acetyltransferase I
and O
introduced O
into O
hepatoma O
cells O
using O
three O
methods O
: O
( O
a O
) O
infection O
with O
a O
Moloney O
murine O
leukemia O
virus O
- O
based O
retrovirus O
, O
( O
b O

Comparable O
amounts O
of O
alpha B
5 I
beta I
1 I
integrin I
were O
isolated O
from O
these O
cells O
by O
chromatography O
of O
detergent O
extracts O
on O
a O
fibronectin B
cell O
- O
binding O
fragment O
affinity O
column O
and O
elution O
with O
EDTA O
. O

Sequence O
analysis O
revealed O
significant O
differences O
between O
the O
5 O
' O
region O
of O
the O
beta O
subunit O
gene O
and O
the O
corresponding O
regions O
of O
the O
homologous B
GlyR I
alpha I
subunit I
genes I
; O
it O
also O
identified O
a O
novel O
exon O
( O
exon O
0 O
) O
that O
encodes O
most O
of O
the O
5 O
' O
- O
untranslated O
portion O
of O
the O
GlyR B
beta I
mRNA I
. O

The O
different O
holoenzyme B
RNA I
polymerases I
generated O
upon O
reconstituting O
these O
mutants O
independently O
with O
core B
RNA I
polymerase I
( O
alpha2beta B
beta I
' I
) O
have O
shown O
reduced O
transcriptional O
activity O
in O
comparison O
to O
the O
enzyme O
containing O
wild B
- I
type I
sigma I
factor I
. O

Because O
the O
human B
Antp I
TATAA I
binding I
protein I
is O
expressed O
in O
both O
lymphoid O
and O
non O
- O
lymphoid O
cells O
, O
we O
suggest O
that O
this O
homeobox B
gene I
has O
evolved O
a O
more O
general O
transcriptional O
regulatory O
function O
in O
higher O
eukaryotic O
cells O
. O

Instead O
, O
they O
contained O
dendritic O
cells O
that O
express O
melanogenic O
marker O
proteins O
such O
as O
tyrosinase B
and O
tyrosinase B
- I
related I
protein I
1 I
. O

We O
used O
stored O
plasma O
samples O
from O
409 O
patients O
in O
the O
National O
Institute O
of O
Neurological O
Diseases O
and O
Stroke O
( O
NINDS O
) O
tissue B
plasminogen I
activator I
( O
t B
- I
PA I
) O
Stroke O
Trial O
to O
examine O
the O
relationship O
between O
an O
apolipoprotein B
( I
Apo I
) I
E2 I
or O
an O
Apo B
E4 I
phenotype O
and O
a O
favorable O
outcome O
3 O
months O
after O
stroke O
, O
the O
risk O
of O
intracerebral O
hemorrhage O
, O
and O
the O
response O
to O
intravenous O
t B
- I
PA I
therapy O
. O

Cytohesin B
- I
1 I
, O
a O
protein O
abundant O
in O
cells O
of O
the O
immune O
system O
, O
has O
been O
proposed O
to O
be O
a O
human O
homolog O
of O
the O
Saccharomyces B
cerevisiae I
Sec7 I
gene I
product I
, O
which O
is O
crucial O
in O
protein O
transport O
. O

Taken O
together O
, O
these O
results O
indicate O
that O
MAP B
kinase I
stimulates O
the O
hPL B
- I
B I
enhancer I
by O
an O
NF B
- I
IL I
- I
6 I
- O
dependent O
pathway O
. O

Substantial O
evidence O
supports O
a O
critical O
role O
for O
the O
activation O
of O
the O
Raf B
- I
1 I
/ O
MEK B
/ O
mitogen B
- I
activated I
protein I
kinase I
pathway O
in O
oncogenic O
Ras B
- O
mediated O
transformation O
. O

A O
reciprocal O
binding O
assay O
using O
IM O
- O
9 O
cells O
as O
a O
source O
of O
SHP B
- I
1 I
and O
SHP B
- I
2 I
revealed O
specific O
association O
of O
SHP B
- I
2 I
( O
but O
not O
SHP B
- I
1 I
) O
with O
a O
glutathione B
S I
- I
transferase I
fusion I
incorporating O
GHR B
cytoplasmic I
domain I
residues I
485 I
- I
620 I
, O
but O
only O
if O
the O
fusion O
was O
first O
rendered O
tyrosine O
- O
phosphorylated O
. O

The O
84 B
. I
1C I
mAb I
recognizes O
a O
site O
on O
IgE B
which O
is O
identical O
or O
very O
close O
to O
the O
Fc B
epsilon I
R I
binding I
site I
, O
and O
95 O
. O
3 O
recognizes O
a O
site O
on O
IgE B
which O
is O
related O
, O
but O
not O
identical O
to O
the O
Fc B
epsilon I
R I
binding I
site I
. O

The O
84 B
. I
1C I
mAb I
recognizes O
a O
site O
on O
IgE B
which O
is O
identical O
or O
very O
close O
to O
the O
Fc B
epsilon I
R I
binding I
site I
, O
and O
95 O
. O
3 O
recognizes O
a O
site O
on O
IgE B
which O
is O
related O
, O
but O
not O
identical O
to O
the O
Fc B
epsilon I
R I
binding I
site I
. O

Tumor B
necrosis I
factor I
signaling O
to O
stress B
- I
activated I
protein I
kinase I
( O
SAPK B
) O
/ O
Jun B
NH2 I
- I
terminal I
kinase I
( O
JNK B
) O
and O
p38 B
. O

Tumor B
necrosis I
factor I
signaling O
to O
stress B
- I
activated I
protein I
kinase I
( O
SAPK B
) O
/ O
Jun B
NH2 I
- I
terminal I
kinase I
( O
JNK B
) O
and O
p38 B
. O

The O
tumor B
- I
suppressor I
protein I
p53 I
is O
involved O
in O
maintaining O
genomic O
stability O
. O

The O
cDNA O
segment O
is O
flanked O
by O
the O
immunoglobulin B
gene I
recombination I
signal I
sequences I
so O
that O
the O
cDNA O
segment O
can O
invert O
and O
the O
human B
IL I
- I
2R I
L I
chain I
is O
subsequently O
expressed O
under O
the O
control O
of O
the O
SV40 B
promoter I
. O

TBP B
can O
be O
phosphorylated O
in O
vitro O
by O
extracts O
of O
U937 O
cells O
or O
by O
bacterially O
expressed O
activated O
ERK2 B
; O
the O
phosphorylation O
sites O
were O
mapped O
to O
ERK B
kinase I
consensus I
sites I
in O
the O
TBP B
amino I
- I
terminal I
domain I
. O

We O
have O
found O
that O
the O
expression O
of O
GTPase B
- O
deficient O
mutants O
of O
alpha B
12 I
( O
alpha B
12Q229L I
) O
or O
alpha B
13 I
( O
alpha B
13Q226L I
) O
leads O
to O
robust O
activation O
of O
the O
Jun B
kinase I
/ O
stress B
- I
activated I
protein I
kinase I
( O
JNK B
/ O
SAPK B
) O
pathway O
. O

Reactivities O
to O
horse B
anti I
- I
lymphocyte I
globulin I
. O

GH B
failed O
to O
stimulate O
phosphorylation O
or O
activation O
of O
Jun B
N I
- I
terminal I
kinase I
under O
the O
conditions O
used O
. O

It O
is O
, O
however O
, O
extremely O
homologous O
to O
a O
third O
' O
non O
- O
classical O
' O
gene O
, O
HLA B
- I
5 I
. I
4 I
, O
and O
to O
the O
chimpanzee O
gene O
, O
Ch28 B
. O

Previously O
, O
we O
showed O
that O
the O
APRE O
is O
a O
cytokine O
[ O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNFalpha B
) O
] O
- O
inducible O
enhancer O
by O
binding O
the O
heterodimeric B
nuclear I
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
complex O
Rel B
A I
x O
NF B
- I
kappaB1 I
. O

Previously O
, O
we O
showed O
that O
the O
APRE O
is O
a O
cytokine O
[ O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNFalpha B
) O
] O
- O
inducible O
enhancer O
by O
binding O
the O
heterodimeric B
nuclear I
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
complex O
Rel B
A I
x O
NF B
- I
kappaB1 I
. O

We O
describe O
a O
genetic O
system O
for O
further O
characterizing O
the O
role O
of O
the O
extreme O
C O
- O
terminus O
of O
the O
beta O
subunit O
of O
E B
. I
coli I
RNA I
polymerase I
. O

When O
ligated O
to O
the O
proIL B
- I
1 I
beta I
cap I
site I
- I
proximal I
region I
( O
located O
between O
- O
131 O
to O
+ O
12 O
) O
, O
both O
the O
proIL B
- I
1 I
beta I
and O
the O
simian B
virus I
40 I
enhancer I
elements I
functioned O
more O
efficiently O
in O
monocytes O
than O
in O
HeLa O
cells O
, O
which O
are O
not O
normally O
competent O
for O
IL B
- I
1 I
beta I
expression O
. O

Molecular O
cloning O
and O
expression O
of O
human B
UDP I
- I
d I
- I
Xylose I
: I
proteoglycan I
core I
protein I
beta B
- I
d I
- I
xylosyltransferase I
and O
its O
first O
isoform B
XT I
- I
II I
. O

CM O
reduced O
the O
nuclear O
binding O
activity O
of O
transcription B
factor I
AP I
- I
1 I
. O

This O
study O
underlines O
the O
importance O
of O
terminal O
SC5b B
- I
9 I
complement I
complex I
as O
a O
suitable O
marker O
in O
the O
evaluation O
of O
complement O
activation O
during O
cardiopulmonary O
bypass O
. O

In O
our O
previous O
studies O
, O
transcriptional O
activation O
was O
shown O
to O
correlate O
with O
IEP86 B
binding O
to O
both O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
and O
the O
transcription O
factor O
bound O
upstream O
. O

Peroxisome B
proliferator I
- I
activated I
receptors I
( O
PPARs B
) O
and O
retinoid B
X I
receptors I
( O
RXRs B
) O
are O
nuclear B
hormone I
receptors I
that O
are O
activated O
by O
fatty O
acids O
and O
9 O
- O
cis O
- O
retinoic O
acid O
, O
respectively O
. O

Examination O
of O
immediate B
- I
early I
transcription I
factor I
expression O
during O
the O
MDI O
regimen O
revealed O
that O
RA O
mediated O
an O
elevated O
, O
prolonged O
expression O
of O
c B
- I
Jun I
mRNA I
accompanied O
by O
diminished O
expression O
of O
c B
- I
Fos I
and O
Jun B
- I
B I
mRNAs I
. O

We O
conclude O
that O
RPMS B
acts O
as O
a O
negative O
regulator O
of O
EBNA2 B
and O
Notch B
activity O
through O
its O
interactions O
with O
the O
CBF1 B
- I
associated I
corepressor I
complex I
. O

Altogether O
these O
results O
suggest O
that O
, O
in O
KG1a O
cells O
, O
TNFalpha B
can O
stimulate O
in O
parallel O
PC B
- I
PLC I
and O
PLD B
, O
whose O
lipid O
products O
activate O
in O
turn O
mitogen B
- I
activated I
protein I
kinase I
( O
MAP B
kinase I
) O
and O
NF B
- I
kappaB I
signalling O
respectively O
. O

Pax B
- I
3 I
is O
a O
paired B
- I
type I
homeobox I
gene I
that O
is O
specifically O
expressed O
in O
the O
dorsal O
and O
posterior O
neural O
tube O
. O

CCAAT B
/ I
enhancer I
- I
binding I
protein I
isoforms I
beta I
and I
delta I
are O
expressed O
in O
mammary O
epithelial O
cells O
and O
bind O
to O
multiple O
sites O
in O
the O
beta B
- I
casein I
gene I
promoter I
. O

The O
deduced O
amino O
acid O
sequence O
has O
the O
greatest O
homology O
( O
61 O
% O
) O
to O
the O
green B
alga I
Scenedemus I
obliquus I
plastocyanin I
. O

From O
sequence O
alignments O
with O
phylogenetically O
related O
viruses O
, O
including O
tymoviruses O
, O
we O
predicted O
that O
p223 B
contained O
a O
papain B
- I
like I
proteinase I
domain I
with O
a O
putative O
catalytic O
cysteine994 O
and O
histidine1075 O
. O

The O
characterized O
Y B
' I
repeated I
sequence I
families I
provide O
an O
experimental O
system O
in O
which O
repeated O
sequence O
interactions O
and O
subsequent O
evolution O
can O
be O
studied O
. O

The O
synthetic O
DNA O
sequence O
was O
constructed O
to O
achieve O
efficient O
base O
pairing O
with O
Escherichia B
coli I
16S I
ribosomal I
RNA I
, O
avoidance O
of O
internal O
secondary O
structure O
, O
and O
optimal O
codon O
usage O
for O
high O
- O
level O
protein O
expression O
in O
accord O
with O
the O
known O
preferences O
in O
E O
. O
coli O
. O

Stable O
expression O
of O
the O
chimeric O
alpha B
i I
( I
54 I
) I
/ I
s I
polypeptide O
in O
Chinese O
hamster O
ovary O
( O
CHO O
) O
cells O
constitutively O
increased O
both O
cAMP O
synthesis O
and O
cAMP B
- I
dependent I
protein I
kinase I
activity O
. O

The O
specific O
interaction O
between O
a O
defined O
structural O
element O
of O
the O
human O
immunodeficiency O
virus O
mRNA O
( O
RRE B
, O
the O
Rev B
response I
element I
) O
and O
the O
virus B
- I
encoded I
protein I
Rev I
has O
been O
implicated O
in O
the O
regulation O
of O
the O
export O
of O
unspliced O
or O
singly O
spliced O
mRNA O
from O
the O
nucleus O
to O
the O
cytoplasm O
. O

Active O
lambda B
and I
kappa I
antibody I
gene I
rearrangement O
in O
Abelson O
murine O
leukemia O
virus O
- O
transformed O
pre O
- O
B O
cell O
lines O
. O

2 O
- O
AP O
induced O
marked O
, O
steady O
rises O
in O
mRNA O
accumulation O
from O
both O
transfected O
and O
chromosomally O
integrated O
HIV O
- O
1 O
constructs O
but O
no O
increases O
from O
an O
endogenous O
gene O
encoding O
gamma B
- I
actin I
or O
glucose B
6 I
- I
phosphate I
dehydrogenase I
. O

The O
serum O
levels O
of O
beta B
- I
human I
chorionic I
gonadotropin I
( O
HCG B
) O
and O
placental B
alkaline I
phosphatase I
( O
PLAP B
) O
were O
not O
elevated O
. O

The O
binding O
of O
transcription O
factor O
AP B
- I
1 I
and O
vitamin B
D I
receptor I
( O
VDR B
) O
to O
the O
composite O
AP B
- I
1 I
plus I
vitamin I
- I
D I
- I
responsive I
promoter I
region O
( O
AP B
- I
1 I
+ I
VDRE I
) O
of O
the O
human B
osteocalcin I
gene I
was O
characterized O
in O
osteocalcin B
- O
producing O
( O
MG O
- O
63 O
) O
and O
non O
- O
producing O
( O
U2 O
- O
Os O
, O
SaOs O
- O
2 O
) O
human O
osteosarcoma O
cell O
lines O
. O

Peroxisome B
proliferator I
- I
activated I
receptors I
( O
PPAR B
) O
modulate O
transcription O
by O
binding O
to O
specific O
peroxisome O
proliferator O
- O
response O
elements O
( O
PPRE O
) O
through O
heterodimerization O
with O
the O
9 B
- I
cis I
retinoic I
acid I
receptor I
( O
RXR B
) O
. O

Luteinizing B
hormone I
- I
releasing I
hormone I
analog O
therapy O
of O
uterine O
fibroid O
: O
analysis O
of O
results O
obtained O
with O
buserelin O
administered O
intranasally O
and O
goserelin O
administered O
subcutaneously O
as O
a O
monthly O
depot O
. O

Analysis O
with O
additional O
anti O
- O
peptide O
antibodies O
specific O
for O
alpha B
, I
beta I
, I
or I
gamma I
PKC I
indicated O
that O
all O
three O
types O
of O
PKC B
are O
expressed O
in O
JK O
cells O
; O
however O
, O
JKPE O
cells O
lost O
a O
major O
approximately O
82 O
kDa O
immunoreactive O
cytosolic O
protein O
detectable O
with O
anti B
- I
PKC I
alpha I
antibody I
. O

The O
predicted O
domain O
structures O
of O
FkbB B
and O
FkbC B
are O
analogous O
to O
that O
of O
FkbA B
and O
comprise O
30 O
fatty B
- I
acid I
- I
synthase I
( O
FAS B
) O
- O
like O
domains O
arranged O
in O
6 O
modules O
. O

An O
amino O
- O
acid O
sequence O
comparison O
revealed O
that O
Bacillus B
YM55 I
- I
1 I
aspartase I
shared O
71 O
% O
homology O
with O
Bacillus B
subtilis I
aspartase I
and O
49 O
% O
with O
Escherichia O
coli O
and O
Pseudomonas B
fluorescens I
aspartases I
. O

The O
titer O
of O
anti B
HSV I
type I
1 I
and O
anti B
HSV I
type I
2 I
antibodies I
in O
the O
mothers O
' O
and O
cord O
blood O
was O
determined O
and O
compared O
. O

The O
primary O
structure O
of O
the O
GAL7 B
5 I
' I
flanking I
region I
has O
many O
features O
common O
to O
those O
of O
multicellular O
eukaryotic O
genes O
. O

Several O
genes O
or O
transcriptional O
units O
were O
identified O
, O
including O
the O
3 O
' O
end O
of O
ribosomal B
s6 I
kinase I
( O
Rsk3 B
) O
; O
two O
apparently O
intronless O
and O
ORF O
- O
less O
genes O
; O
and O
Gpr31 B
, O
an O
intronless O
, O
putative O
G B
- I
protein I
coupled I
receptor I
. O

Toward O
this O
end O
, O
we O
prepared O
synthetic O
proteins O
with O
either O
the O
catalytic O
domain O
of O
FAP B
- I
1 I
( I
C I
- I
terminal I
399 I
amino I
acids I
) I
or O
its O
inactive O
form O
( O
Cys2408 O
- O
- O
> O
Ser O
) O
fused O
to O
glutathione B
- I
S I
- I
transferase I
( O
GST B
) O
. O

TGF B
beta I
1 I
expression O
is O
largely O
governed O
by O
three O
AP B
- I
1 I
binding I
sites I
located O
in O
two O
different O
promoters O
of O
this O
gene O
. O

Mitochondrial B
Mas70p I
signal I
anchor I
sequence I
. O

Transcriptional O
regulation O
of O
the O
mouse B
cytosolic I
chaperonin I
subunit I
gene I
Ccta B
/ I
t I
- I
complex I
polypeptide I
1 I
by O
selenocysteine B
tRNA I
gene I
transcription I
activating I
factor I
family I
zinc I
finger I
proteins I
. O

The O
recognition O
specificity O
of O
the O
p55 B
PDZ B
domain I
appears O
to O
be O
unique O
, O
since O
the O
three O
PDZ B
domains I
of O
hDlg B
( O
human O
lymphocyte O
homologue O
of O
the O
Drosophila B
discs I
large I
tumor I
suppressor I
) O
do O
not O
bind O
the O
cytoplasmic O
domain O
of O
glycophorin B
C I
. O

Cytosolic B
acetyl I
- I
CoA I
synthetase I
( O
AceCS1 B
) O
activates O
acetate O
to O
supply O
the O
cells O
with O
acetyl O
- O
CoA O
for O
lipid O
synthesis O
. O

These O
results O
demonstrate O
the O
existence O
of O
different O
PI B
3 I
- I
kinase I
isoforms I
and O
define O
a O
family O
of O
genes O
encoding O
distinct O
PI B
3 I
- I
kinase I
catalytic I
subunits I
that O
can O
associate O
with O
p85 B
. O

P B
- I
CIP1 I
, O
a O
novel O
protein O
that O
interacts O
with O
the O
cytosolic O
domain O
of O
peptidylglycine B
alpha I
- I
amidating I
monooxygenase I
, O
is O
associated O
with O
endosomes O
. O

In O
vitro O
interaction O
studies O
, O
using O
proteins O
fused O
to O
glutathione B
- I
S I
- I
transferase I
, O
showed O
that O
RBP B
- I
J I
kappa I
and O
Su B
( I
H I
) I
bind O
directly O
to O
the O
RAM23 B
regions I
of O
mouse B
Notch1 I
and O
Drosophila B
Notch I
, O
respectively O
. O

The O
telomerase B
RNA I
- I
protein I
complex I
responsible O
for O
maintenance O
of O
telomeric O
DNA O
at O
chromosome O
ends O
, O
is O
usually O
inactive O
in O
most O
primary O
somatic O
human O
cells O
, O
but O
is O
specifically O
activated O
with O
in O
vitro O
immortalization O
and O
during O
tumorigenesis O
. O

An O
approximately O
2 B
- I
kilobase I
B2 I
transcript I
was O
expressed O
in O
all O
alfalfa O
organs O
tested O
. O

These O
data O
locate O
the O
aniridia B
gene I
( O
AN2 B
) O
and O
a O
recurrent O
T B
- I
cell I
leukemia I
breakpoint I
( O
TCL2 B
) O
in O
the O
marker O
sequence O
, O
on O
opposite O
sides O
of O
MIC1 B
. O

Analysis O
of O
the O
protein O
sequences O
of O
these O
two O
replicases B
, O
together O
with O
previously O
characterized O
H B
. I
pylori I
plasmid I
replication I
proteins I
, O
supports O
the O
formation O
of O
a O
distinct O
class O
of O
H B
. I
pylori I
plasmid I
proteins I
. O

These O
cells O
produced O
P2Y B
( I
11 I
) I
mRNA I
during O
culture O
. O

We O
have O
been O
studying O
the O
interaction O
of O
the O
oncogenic O
human O
polyomavirus O
BK O
( O
BKV O
) O
with O
the O
tumor B
- I
suppressor I
protein I
p53 I
to O
understand O
the O
biology O
of O
this O
virus O
as O
well O
as O
to O
understand O
the O
basic O
mechanisms O
of O
p53 B
transactivation O
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM B
- I
1 I
promoter I
performed O
with O
chloramphenicol B
acetyltransferase I
constructs I
revealed O
that O
Tax B
was O
trans O
activating O
the O
VCAM B
- I
1 I
promoter I
via O
two O
NF B
- I
kappaB I
sites I
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM B
- I
1 I
gene I
promoter I
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax B
- O
induced O
expression O
of O
this O
adhesion O
molecule O
. O

The O
CVA16 B
. I
4 I
proteolipid I
transcript I
is O
the O
most O
prevalent O
of O
the O
two O
proteolipid O
messages O
in O
expanding O
ovules O
harvested O
10 O
d O
post O
- O
anthesis O
. O

Enhancer O
and O
promoter O
elements O
directing O
activation O
and O
glucocorticoid O
repression O
of O
the O
alpha B
1 I
- I
fetoprotein I
gene I
in O
hepatocytes O
. O

CONCLUSIONS O
: O
XCoe2 B
may O
play O
a O
pivotal O
role O
in O
the O
transcriptional O
cascade O
that O
specifies O
primary O
neurons O
in O
Xenopus O
embryos O
: O
by O
maintaining O
Delta B
- O
Notch B
signalling O
, O
XCoe2 B
stabilises O
the O
higher O
neural O
potential O
of O
selected O
progenitor O
cells O
that O
express O
X B
- I
ngnr I
- I
1 I
, O
ensuring O
the O
transition O
between O
neural O
competence O
and O
irreversible O
commitment O
to O
a O
neural O
fate O
; O
and O
it O
promotes O
neuronal O
differentiation O
by O
activating O
XNeuroD B
expression O
, O
directly O
or O
indirectly O
. O

The O
evolution O
of O
the O
CCR5 B
cis I
- I
regulatory I
region I
versus O
the O
open O
reading O
frame O
as O
well O
as O
among O
different O
domains O
of O
the O
open O
reading O
frame O
differed O
from O
one O
another O
. O

